| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net income (loss) | 25,677 | -19,040 |
| Depreciation and amortization expense | 661 | 661 |
| Stock-based compensation expense | 1,360 | 939 |
| Reduction in the operating right of use assets | 1,265 | 1,233 |
| Write-off of deferred financing costs | 208 | 208 |
| Loss on sale of assets held for sale | -3,219 | -3,539 |
| Gain (loss) on sale of property and equipment | 113 | 113 |
| Non-cash interest expense | 31 | 31 |
| Loss on abandonment of operating lease right-of-use asset | 927 | 927 |
| Gain on sale of sale-leaseback | 0 | - |
| Prepaid expenses and other assets | -2,523 | -3,328 |
| Accounts payable | 3,091 | 1,951 |
| Accrued expenses | -6,360 | -4,922 |
| Deferred revenue | -44,979 | -3,729 |
| Operating lease liabilities | -1,630 | -1,041 |
| Other long term liabilities | 57 | 57 |
| Net cash used in operating activities | -14,063 | -15,971 |
| Proceeds from sales of assets held for sale | 163 | 163 |
| Proceeds from sales of property and equipment | 524 | 524 |
| Purchases of property and equipment | 0 | 0 |
| Net cash provided by (used in) investing activities | 687 | 687 |
| Payment of principal related to finance lease liabilities | 244 | 304 |
| Proceeds from failed sale-leaseback arrangement | 0 | 0 |
| Payment of finance liability from failed sale-leaseback arrangements | 1,517 | 327 |
| Proceeds from the exercise of stock options | 5 | 5 |
| Sale of common stock under open market sale agreement, net of issuance costs | 0 | 0 |
| Net cash (used in) provided by financing activities | -1,756 | -626 |
| Net decrease in cash, cash equivalents and restricted cash | -15,132 | -15,910 |
| Cash and cash equivalents at beginning of period | 17,909 | - |
| Cash and cash equivalents at end of period | 2,777 | - |
Carisma Therapeutics Inc. (CARM)
Carisma Therapeutics Inc. (CARM)